Scott Bizily - Feb 8, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal Officer
Signature
By: /s/ Scott Bizily
Stock symbol
FDMT
Transactions as of
Feb 8, 2024
Transactions value $
-$108,124
Form type
4
Date filed
2/12/2024, 09:04 PM
Previous filing
Dec 13, 2023
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $8.64K +1.33K +76.68% $6.49 3.07K Feb 8, 2024 Direct F1
transaction FDMT Common Stock Sale -$36.6K -1.33K -43.4% $27.50 1.74K Feb 8, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $23.4K +2.92K +167.88% $8.04 4.65K Feb 8, 2024 Direct F1
transaction FDMT Common Stock Sale -$80.2K -2.92K -62.67% $27.50 1.74K Feb 8, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $31.5K +2K +114.91% $15.78 3.73K Feb 8, 2024 Direct F1
transaction FDMT Common Stock Sale -$54.9K -2K -53.47% $27.50 1.74K Feb 8, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -1.33K -7.25% $0.00 17K Feb 8, 2024 Common Stock 1.33K $6.49 Direct F1, F2
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -2.92K -5.98% $0.00 45.8K Feb 8, 2024 Common Stock 2.92K $8.04 Direct F1, F3
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -2K -7.98% $0.00 23K Feb 8, 2024 Common Stock 2K $15.78 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F4 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.